Drug Demand Reduction Act
Drug abuse legislation (H.R. 4550) passes House Sept. 16 with provision directing HHS to conduct a study regarding the need for financial incentives to encourage the development of anti-addiction drugs. Bill managers Portman (R-Ohio) and Hastert (R-Ill.) proposed the amendment in response to initial bill language that would have given manufacturers of anti-addiction products the right to extend the exclusivity of a different marketed product upon the approval of the anti-addiction agent
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth